| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2893.2000.00210.X |
| P8608 | Fatcat ID | release_3ypycusskrdmhmbwwgxjfhffe4 |
| P698 | PubMed publication ID | 10760047 |
| P50 | author | Erik De Clercq | Q13578863 |
| P2093 | author name string | E De Clercq | |
| J Neyts | |||
| C Ying | |||
| P Furman | |||
| W Nicholson | |||
| P2860 | cites work | Preclinical aspects of lamivudine and famciclovir against hepatitis B virus | Q33801322 |
| Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus | Q39779598 | ||
| A novel selective broad-spectrum anti-DNA virus agent | Q40804246 | ||
| Therapy of viral hepatitis | Q40846342 | ||
| Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines | Q41270617 | ||
| Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies | Q41617111 | ||
| Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection | Q42288008 | ||
| Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice | Q42537195 | ||
| Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro | Q44820781 | ||
| Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus | Q45750532 | ||
| Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment | Q45756075 | ||
| Biotransformation and pharmacokinetics of prodrug 9-(beta-D-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(beta-D-1,3-dioxolan-4-yl)guanine in mice | Q48643124 | ||
| P433 | issue | 2 | |
| P921 | main subject | Hepatitis B virus | Q6844 |
| tenofovir | Q155954 | ||
| P304 | page(s) | 161-165 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
| P1476 | title | Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir | |
| P478 | volume | 7 |
| Q34373532 | Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. |
| Q39859839 | Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues |
| Q40820975 | Anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl] x guanine (A-5021) in vitro and in vivo. |
| Q33883722 | Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection |
| Q36094811 | Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection |
| Q36932959 | Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection |
| Q44036705 | Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus |
| Q36607389 | Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo |
| Q36492635 | Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis |
| Q28365198 | Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus |
| Q35535861 | Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety |
| Q37760897 | Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation |
| Q40073982 | Development of a novel mouse model to evaluate drug candidates against hepatitis B virus |
| Q45355457 | Differentiated umbilical cord matrix stem cells as a new in vitro model to study early events during hepatitis B virus infection |
| Q56786248 | Discovery and Development of Tenofovir Disoproxil Fumarate |
| Q34363078 | Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. |
| Q37564039 | Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. |
| Q35048263 | Emerging therapies of hepatitis B and C. |
| Q35014297 | Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening |
| Q36140666 | HIV-1/hepatitis B coinfection |
| Q35007583 | Hepatitis B virus resistance to lamivudine and its clinical implications |
| Q28345952 | In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil |
| Q33676340 | Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals |
| Q37772508 | Management of HIV and hepatitis virus coinfection |
| Q41091378 | Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities |
| Q39673548 | Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study |
| Q36485086 | Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses |
| Q34112556 | Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro |
| Q33968358 | Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. |
| Q44035057 | Reactivation of viral replication after replacement of tenofovir by adefovir |
| Q36632233 | Recommendations and potential future options in the treatment of hepatitis B. |
| Q40654775 | Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity |
| Q34299035 | Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation |
| Q36388364 | Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. |
| Q35987869 | Review article: Nucleoside analogues for the treatment of chronic hepatitis B. |
| Q40837854 | Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. |
| Q58098975 | Role of tenofovir in the treatment of chronic HBV infection |
| Q46718131 | Short communication cellular pharmacology of 9-(beta-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes |
| Q45450320 | Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results |
| Q40417514 | Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. |
| Q45397929 | Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression |
| Q46607007 | Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration |
| Q44418225 | Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. |
| Q41435482 | Tenofovir and its potential in the treatment of hepatitis B virus. |
| Q34534058 | Tenofovir disoproxil fumarate |
| Q46044243 | Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. |
| Q44797474 | Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. |
| Q33426123 | Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection |
| Q45126707 | Tenofovir therapy for lamivudine resistance following liver transplantation |
| Q35621741 | Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus |
| Q37754603 | Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future |
| Q33940140 | Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations |
| Q53854337 | Update on Hepatitis B and C Coinfection in HIV. |
| Q45441520 | Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants |
| Q35617319 | Viral hepatitis B. |
Search more.